NASDAQ:ATRA
Atara Biotherapeutics Stock News
$0.690
-0.0098 (-1.40%)
At Close: Apr 26, 2024
Atara Biotherapeutics to Participate at Two Upcoming Conferences
08:01pm, Thursday, 04'th Jun 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including soli
Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy
02:17pm, Thursday, 04'th Jun 2020
CAMBRIDGE, Mass., June 4, 2020 /PRNewswire via COMTEX/ --
CAMBRIDGE, Mass., June 4, 2020 /PRNewswire/ -- Artax Biopharma, Inc., a biotechnology company...
Adams Resources & Energy: A Bet On Oil And Management (NYSEMKT:AE)
08:39pm, Sunday, 31'st May 2020
Crude oil prices are still the primary driver of earnings. Recent acquisitions lead to an increased focus on the transportation segment. New management across t
Xconomy: Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem's Approval & More
01:46pm, Friday, 29'th May 2020
A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the
Love Island doughnut maker expanding into Chesterfield
06:52pm, Wednesday, 27'th May 2020
They've even whipped up orders for Royalty
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
11:25am, Wednesday, 27'th May 2020Atara Biotherapeutics Prices 12.6M Share Public Offering @$11.32/Share
09:44am, Wednesday, 27'th May 2020Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
05:16am, Wednesday, 27'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases i
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
12:00am, Wednesday, 27'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transforma
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants; No Terms Disclosed
08:09pm, Tuesday, 26'th May 2020Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
08:05pm, Tuesday, 26'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases i
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including sol
